Our top pick for
Building a portfolio
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Axon Enterprise, Inc is an aerospace & defense business based in the US. Axon Enterprise shares (AXON) are listed on the NASDAQ and all prices are listed in US Dollars. Axon Enterprise employs 1,710 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$140.59|
|52-week range||$78.28 - $212.37|
|50-day moving average||$146.78|
|200-day moving average||$149.05|
|Wall St. target price||$177.75|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$0.25|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-06-25)||N/A|
|1 month (2021-06-02)||N/A|
|3 months (2021-04-05)||-3.92%|
|6 months (2021-01-05)||14.96%|
|1 year (2020-07-02)||40.11%|
|2 years (2019-07-05)||119.47%|
|3 years (2018-07-05)||116.36%|
|5 years (2016-07-05)||460.12%|
Valuing Axon Enterprise stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Axon Enterprise's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Axon Enterprise's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 2.86. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Axon Enterprise's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Axon Enterprise's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $18.6 million.
The EBITDA is a measure of a Axon Enterprise's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||$728.9 million|
|Gross profit TTM||$416.3 million|
|Return on assets TTM||-2.37%|
|Return on equity TTM||-6.84%|
|Market capitalisation||$11.2 billion|
TTM: trailing 12 months
There are currently 1.6 million Axon Enterprise shares held short by investors – that's known as Axon Enterprise's "short interest". This figure is 55.8% up from 1.0 million last month.
There are a few different ways that this level of interest in shorting Axon Enterprise shares can be evaluated.
Axon Enterprise's "short interest ratio" (SIR) is the quantity of Axon Enterprise shares currently shorted divided by the average quantity of Axon Enterprise shares traded daily (recently around 414898.68766404). Axon Enterprise's SIR currently stands at 3.81. In other words for every 100,000 Axon Enterprise shares traded daily on the market, roughly 3810 shares are currently held short.
However Axon Enterprise's short interest can also be evaluated against the total number of Axon Enterprise shares, or, against the total number of tradable Axon Enterprise shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Axon Enterprise's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Axon Enterprise shares in existence, roughly 20 shares are currently held short) or 0.0249% of the tradable shares (for every 100,000 tradable Axon Enterprise shares, roughly 25 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Axon Enterprise.
Find out more about how you can short Axon Enterprise stock.
We're not expecting Axon Enterprise to pay a dividend over the next 12 months.
Axon Enterprise's shares were split on a 2:1 basis on 29 November 2004. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your Axon Enterprise shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for Axon Enterprise shares which in turn could have impacted Axon Enterprise's share price.
Over the last 12 months, Axon Enterprise's shares have ranged in value from as little as $78.28 up to $212.37. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Axon Enterprise's is 0.4777. This would suggest that Axon Enterprise's shares are less volatile than average (for this exchange).
Axon Enterprise, Inc. develops, manufactures, and sells conducted energy weapons (CEWs) under the TASER brand in the United States and internationally. It operates through two segments, TASER and Software and Sensors. The company offers TASER X26P, TASER X2, TASER 7, and TASER Pulse CEWs; and related cartridges. It also provides on-officer body cameras and Axon Fleet in-car video systems; and Axon Evidence digital evidence management software; Axon Records, a cloud-based records management system; Axon Signal enabled devices; and computer-aided dispatch software, as well as Axon docks, cartridges, and batteries. In addition, the company offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence. It sells its products through its direct sales force, distribution partners, online store, and third-party resellers.
Everything we know about the Huake Holding Biology Co IPO, plus information on how to buy in.
Everything we know about the Outbrain IPO, plus information on how to buy in.
Everything we know about the Duolingo IPO, plus information on how to buy in.
Everything we know about the Elicio Therapeutics IPO, plus information on how to buy in.
Everything we know about the Paltalk IPO, plus information on how to buy in.
Everything we know about the Instructure Holdings IPO, plus information on how to buy in.
Everything we know about the Ipsidy IPO, plus information on how to buy in.
Everything we know about the ScoutCam IPO, plus information on how to buy in.
Everything we know about the Candel Therapeutics IPO, plus information on how to buy in.
Everything we know about the Xponential Fitness IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.